154 related articles for article (PubMed ID: 15148627)
1. Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer.
Sorscher SM
Cancer Chemother Pharmacol; 2004 Aug; 54(2):191-2. PubMed ID: 15148627
[TBL] [Abstract][Full Text] [Related]
2. Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
Wright JL; Lin DW; Dewan P; Montgomery RB
Int J Urol; 2005 Nov; 12(11):1012-3. PubMed ID: 16351664
[TBL] [Abstract][Full Text] [Related]
3. Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer.
Ajzensztejn D; Hegde VS; Lee SM
J Clin Oncol; 2006 May; 24(15):2389-91. PubMed ID: 16710040
[No Abstract] [Full Text] [Related]
4. Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel.
Bhardwaj S; Varma S
J Oncol Pharm Pract; 2018 Mar; 24(2):153-155. PubMed ID: 29284359
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Urakami S; Yoshino T; Kikuno N; Imai S; Honda S; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
Urology; 2005 Mar; 65(3):543-8. PubMed ID: 15780373
[TBL] [Abstract][Full Text] [Related]
6. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
Baeksgaard L; Sørensen JB
Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
[TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer.
Wilkes GM
Oncology (Williston Park); 2010 Oct; 24(10 Suppl):46-8. PubMed ID: 21275327
[No Abstract] [Full Text] [Related]
8. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Ansari J; Hussain SA; Zarkar A; Tanguay JS; Bliss J; Glaholm J
Oncol Rep; 2008 Oct; 20(4):891-6. PubMed ID: 18813832
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of docetaxel in the management of androgen independent prostate cancer.
Khan MA; Carducci M; Partin AW
J Urol; 2003 Nov; 170(5):1709-16. PubMed ID: 14532760
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
12. Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer.
Yahata T; Nishikawa N; Aoki Y; Tanaka K
Gynecol Oncol; 2006 Nov; 103(2):752-4. PubMed ID: 16857250
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.
Gupta S; Silliman CG; Trump DL
Prostate Cancer Prostatic Dis; 2007; 10(4):396-7. PubMed ID: 17404582
[TBL] [Abstract][Full Text] [Related]
14. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
[TBL] [Abstract][Full Text] [Related]
15. Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers.
Berger AP; Niescher M; Fischer-Colbrie R; Pelzer A; Bartsch G; Horninger W
Urol Int; 2004; 73(2):110-2. PubMed ID: 15331892
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
17. Tumor lysis syndrome in metastatic breast cancer after a single dose of paclitaxel.
Vaidya GN; Acevedo R
Am J Emerg Med; 2015 Feb; 33(2):308.e1-2. PubMed ID: 25178848
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.
Beer TM; Eilers KM; Garzotto M; Hsieh YC; Mori M
Cancer; 2004 Feb; 100(4):758-63. PubMed ID: 14770432
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Jones SE; Erban J; Overmoyer B; Budd GT; Hutchins L; Lower E; Laufman L; Sundaram S; Urba WJ; Pritchard KI; Mennel R; Richards D; Olsen S; Meyers ML; Ravdin PM
J Clin Oncol; 2005 Aug; 23(24):5542-51. PubMed ID: 16110015
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
